{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:05:22Z","timestamp":1781787922671,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011634","name":"Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94373-8","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:07:49Z","timestamp":1743116869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Dipak","family":"Walunj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Egarmina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Zipin-Roitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva Sai Naga Anurag","family":"Muddineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Tkachenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousali","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Tobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrii","family":"Bazylevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Milyavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oshrat","family":"Hershkovitz-Rokah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Gellerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"94373_CR1","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3390\/molecules260926012","volume":"26","author":"M Szumilak","year":"2021","unstructured":"Szumilak, M., Wiktorowska-Owczarek, A. & Stanczak, A. Hybrid drugs\u2014A strategy for overcoming anticancer drug resistance?? Molecules 26, 2601. https:\/\/doi.org\/10.3390\/molecules260926012 (2021).","journal-title":"Molecules"},{"key":"94373_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.2174\/1568026616666160927160620","volume":"17","author":"O de Pedrosa","year":"2017","unstructured":"de Pedrosa, O. Hybrid compounds as direct multitarget ligands: A review. Curr. Top. Med. Chem. 17, 1044\u20131079. https:\/\/doi.org\/10.2174\/1568026616666160927160620 (2017).","journal-title":"Curr. Top. Med. Chem."},{"key":"94373_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ejmech.2017.06.066","volume":"138","author":"Y Gilad","year":"2017","unstructured":"Gilad, Y. et al. Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma. Eur. J. Med. Chem. 138, 602\u2013615. https:\/\/doi.org\/10.1016\/j.ejmech.2017.06.066 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"94373_CR4","doi-asserted-by":"publisher","first-page":"113811","DOI":"10.1016\/j.ejmech.2021.113811","volume":"225","author":"D Walunj","year":"2021","unstructured":"Walunj, D. et al. Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating\/methylating dual-action chimera Amonafidazene. Eur. J. Med. Chem. 225, 113811. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113811 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"94373_CR5","first-page":"2115","volume":"11","author":"N Ohsawa","year":"1984","unstructured":"Ohsawa, N., Yamazaki, Z., Wagatsuma, T. & Isurugi, K. Bestrabacil: a possible target-oriented anticancer agent. Gan Kagaku Ryoho. 11, 2115\u20132124 (1984).","journal-title":"Gan Kagaku Ryoho"},{"key":"94373_CR6","doi-asserted-by":"publisher","first-page":"11748","DOI":"10.1021\/ja505212y","volume":"136","author":"P Huang","year":"2014","unstructured":"Huang, P. et al. Combination of small molecule prodrug and nanodrug delivery: amphiphilic Drug\u2013Drug conjugate for cancer therapy. J. Am. Chem. Soc. 136, 11748\u201311756. https:\/\/doi.org\/10.1021\/ja505212y (2014).","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"94373_CR7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","volume":"72","author":"T Haider","year":"2020","unstructured":"Haider, T., Pandey, V., Banjare, N., Gupta, P. N. & Soni, V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol. Rep. 72 (5), 1125\u20131151. https:\/\/doi.org\/10.1007\/s43440-020-00138-7 (2020).","journal-title":"Pharmacol. Rep."},{"key":"94373_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S. & Baradaran, B. The different mechanisms of cancer drug resistance: A brief review. Adv. Pharm. Bull. 7, 339\u2013334. https:\/\/doi.org\/10.15171\/apb.2017.041 (2017).","journal-title":"Adv. Pharm. Bull."},{"key":"94373_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S. & Longley, D. B. Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer. 13, 714\u2013726. https:\/\/doi.org\/10.1038\/nrc3599 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"94373_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang, X., Zhang, H. & Chen, X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2, 141\u2013160. https:\/\/doi.org\/10.20517\/cdr.2019.10 (2019).","journal-title":"Cancer Drug Resist."},{"key":"94373_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41419-019-1593-2","volume":"10","author":"S Berrazouane","year":"2019","unstructured":"Berrazouane, S. et al. Beta1 integrin Blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia. Cell. Death Dis. 10, 357. https:\/\/doi.org\/10.1038\/s41419-019-1593-2 (2019).","journal-title":"Cell. Death Dis."},{"issue":"10","key":"94373_CR12","doi-asserted-by":"publisher","first-page":"e1003302","DOI":"10.1371\/journal.pcbi.1003302","volume":"9","author":"M Gao","year":"2013","unstructured":"Gao, M. & Skolnick, J. A. Comprehensive survey of Small-Molecule binding pockets in proteins. PLOS Comp. Bio. 9 (10), e1003302. https:\/\/doi.org\/10.1371\/journal.pcbi.1003302 (2013).","journal-title":"PLOS Comp. Bio"},{"key":"94373_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/leu.2017.174","volume":"32","author":"S Tharkar-Promod","year":"2018","unstructured":"Tharkar-Promod, S. et al. HDAC1,2 Inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia 32, 49\u201360. https:\/\/doi.org\/10.1038\/leu.2017.174 (2018).","journal-title":"Leukemia"},{"key":"94373_CR14","doi-asserted-by":"publisher","first-page":"10272","DOI":"10.1016\/j.pdpdt.2022.102722","volume":"37","author":"E Thankarajan","year":"2022","unstructured":"Thankarajan, E. et al. A novel, dual action chimera comprising DNA methylating agent and near-IR xanthene-cyanine photosensitizer for combined anticancer therapy. Photodiagn. Photodyn. Ther. 37, 10272. https:\/\/doi.org\/10.1016\/j.pdpdt.2022.102722 (2022).","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"94373_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/ijo.2021.5275","volume":"59","author":"A Blyufer","year":"2021","unstructured":"Blyufer, A. et al. A neuroprotective drug with potential as a novel anti\u2013cancer agent (Review). Int. J. Oncol. 59, 95. https:\/\/doi.org\/10.3892\/ijo.2021.5275 (2021).","journal-title":"Int. J. Oncol."},{"key":"94373_CR16","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy, A. et al. Single-agent Lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J. Clin. Oncol. 31, 3688\u20133695. https:\/\/doi.org\/10.1200\/JCO.2013.49.2835 (2013).","journal-title":"J. Clin. Oncol."},{"key":"94373_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard, J. P. et al. AUGMENT trial investigators, AUGMENT: A phase III study of Lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 37, 1188\u20131199. https:\/\/doi.org\/10.1200\/JCO.19.00010 (2019).","journal-title":"J. Clin. Oncol."},{"key":"94373_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajh.2830430307","volume":"43","author":"G Schiller","year":"1993","unstructured":"Schiller, G., Lee, M., Territo, M., Gajewski, J. & Nimer, S. Phase II study of Etoposide, Ifosfamide, and Mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. Am. J. Hematol. 43, 195\u2013199. https:\/\/doi.org\/10.1002\/ajh.2830430307 (1993).","journal-title":"Am. J. Hematol."},{"key":"94373_CR19","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1200\/JCO.1991.9.7.1210","volume":"9","author":"S Amadori","year":"1991","unstructured":"Amadori, S. et al. Mitoxantrone, Etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. JCO 9, 1210\u20131214. https:\/\/doi.org\/10.1200\/JCO.1991.9.7.1210 (1991).","journal-title":"JCO"},{"key":"94373_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/hon.2949","volume":"40","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. A salvage therapy with Dara-KDT-P(A)CE in heavily pretreated, high-risk, proliferative, relapsed\/refractory multiple myeloma. Hematol. Oncol. 40, 202\u2013211. https:\/\/doi.org\/10.1002\/hon.2949 (2022).","journal-title":"Hematol. Oncol."},{"key":"94373_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang, L. N., Lee, S. H. R., Yang, J. J. & Schmiegelow, K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia 36, 1749\u20131758. https:\/\/doi.org\/10.1038\/s41375-022-01591-4 (2022).","journal-title":"Leukemia"},{"key":"94373_CR22","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/s0889-8588(05)70192-1","volume":"14","author":"Garcia-Manero","year":"2000","unstructured":"Garcia-Manero & Kantarjian, G. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol. Oncol. Clin. North. Am. 14, 1381\u20131396. https:\/\/doi.org\/10.1016\/s0889-8588(05)70192-1 (2000). x\u2013xi.","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"94373_CR23","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7","volume":"7","author":"E Jabbour","year":"2020","unstructured":"Jabbour, E. et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a single-arm, phase 2 trial. Lancet Hematol. 7, e523\u2013e533. https:\/\/doi.org\/10.1016\/S2352-3026(20)30144-7 (2020).","journal-title":"Lancet Hematol."},{"key":"94373_CR24","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","volume":"27","author":"A Engert","year":"2009","unstructured":"Engert, A. et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 27, 4548\u20134554. https:\/\/doi.org\/10.1200\/JCO.2008.19.8820 (2009).","journal-title":"J. Clin. Oncol."},{"key":"94373_CR25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy, K. et al. Dose-Adjusted EPOCH-Rituximab therapy in primary mediastinal B-Cell lymphoma. N Engl. J. Med. 368, 1408\u20131416 (2013). https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1214561","journal-title":"N Engl. J. Med."},{"key":"94373_CR26","doi-asserted-by":"publisher","unstructured":"G\u0103man, A. M., Egbuna, C. & G\u0103man, M. A. Chap. 6 - Natural bioactive lead compounds effective against hematological malignancies, in: Egbuna, C., Kumar, S., Ifemeje, J. C., Ezzat, S. M. & Kaliyaperumal, S. (Eds.), Phytochemicals as Lead Compounds for New Drug Discovery. Elsevier, 95\u2013115 (2020). https:\/\/doi.org\/10.1016\/B978-0-12-817890-4.00006-8","DOI":"10.1016\/B978-0-12-817890-4.00006-8"},{"key":"94373_CR27","doi-asserted-by":"publisher","first-page":"916528","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran, T. B. et al. Multidrug resistance in cancer: Understanding molecular mechanisms, Immunoprevention and therapeutic approaches. Front. Oncol. 12, 916528. https:\/\/doi.org\/10.3389\/fonc.2022.891652 (2022).","journal-title":"Front. Oncol."},{"issue":"2","key":"94373_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"K Chatterjee","year":"2010","unstructured":"Chatterjee, K., Zhang, J., Honbo, N. & Karliner, J. S. Doxorubicin cardiomyopathy. Cardiology 115 (2), 155\u2013162. https:\/\/doi.org\/10.1159\/000265166 (2010).","journal-title":"Cardiology"},{"key":"94373_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"J Hughes","year":"2011","unstructured":"Hughes, J., Rees, S., Kalindjian, S. & Philpott, K. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239\u20131249. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01127.x (2011).","journal-title":"Br. J. Pharmacol."},{"key":"94373_CR30","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.bbamcr.2011.03.002","volume":"1813","author":"AV Kuznetsov","year":"2011","unstructured":"Kuznetsov, A. V., Margreiter, R., Amberger, A., Saks, V. & Grimm, M. Changes in mitochondrial redox State, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochim. Biophys. Acta. 1813, 1144\u20131152. https:\/\/doi.org\/10.1016\/j.bbamcr.2011.03.002 (2011).","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"94373_CR31","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/nar\/gkz11392024)","volume":"48","author":"I Eke","year":"2020","unstructured":"Eke, I. et al. 53BP1\/RIF1 signaling promotes cell survival after multifractionated radiotherapy. Nucleic Acids Res. 48 (3), 1314\u20131326. https:\/\/doi.org\/10.1093\/nar\/gkz11392024) (2020).","journal-title":"Nucleic Acids Res."},{"key":"94373_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1021\/acschembio.2c00022","volume":"17","author":"RL Svec","year":"2022","unstructured":"Svec, R. L. et al. Novel Imidazotetrazine evades known resistance mechanisms and is effective against Temozolomide-Resistant brain cancer in cell culture. ACS Chem. Biol. 17, 299\u2013313. https:\/\/doi.org\/10.1021\/acschembio.2c00022 (2022).","journal-title":"ACS Chem. Biol."},{"key":"94373_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.dnarep.2004.05.004","volume":"3","author":"F Drabl\u00f8s","year":"2004","unstructured":"Drabl\u00f8s, F. et al. Alkylation damage in DNA and RNA\u2013repair mechanisms and medical significance. DNA Repair. (Amst). 3, 1389\u20131140. https:\/\/doi.org\/10.1016\/j.dnarep.2004.05.004 (2004).","journal-title":"DNA Repair. (Amst)"},{"key":"94373_CR34","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41375-018-0315-6","volume":"33","author":"M Scherr","year":"2019","unstructured":"Scherr, M. et al. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL\u2009+\u2009acute lymphoblastic leukemia. Leukemia 33, 1313\u20131323. https:\/\/doi.org\/10.1038\/s41375-018-0315-6 (2019).","journal-title":"Leukemia"},{"key":"94373_CR35","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1182\/blood-2012-10-464677","volume":"121","author":"M Wunderlich","year":"2013","unstructured":"Wunderlich, M. et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 121, e90\u201397. https:\/\/doi.org\/10.1182\/blood-2012-10-464677 (2013).","journal-title":"Blood"},{"key":"94373_CR36","unstructured":"Bank, R. P. D. & Homepage, R. C. S. B. P. D. B. (n.d.). (2024). https:\/\/www.rcsb.org\/(accessed January 26."},{"key":"94373_CR37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1126\/science.1204117","volume":"333","author":"CC Wu","year":"2011","unstructured":"Wu, C. C. et al. Structural basis of type II topoisomerase Inhibition by the anticancer drug Etoposide. Science 333, 459\u2013462. https:\/\/doi.org\/10.1126\/science.1204117 (2011).","journal-title":"Science"},{"key":"94373_CR38","unstructured":"Schr\u00f6dinger - Physics-based Software Platform for Molecular. Discovery & Design, (n.d.). (2024). https:\/\/newsite.schrodinger.com\/(accessed January 26."},{"key":"94373_CR39","unstructured":"Mmauck Schr\u00f6dinger solutions for small molecule protonation state enumeration and pKa prediction, Schr\u00f6dinger (2023). https:\/\/newsite.schrodinger.com\/materials-science\/learn\/white-papers\/schrodinger-solutions-small-molecule-protonation-state-enumeration-and-pka\/(accessed January 26, 2024)."},{"key":"94373_CR40","unstructured":"Life Science. Glide, Schr\u00f6dinger (n.d.). (2024). https:\/\/newsite.schrodinger.com\/platform\/products\/glide\/(accessed January 26."},{"key":"94373_CR41","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1021\/jm060522a","volume":"49","author":"PD Lyne","year":"2006","unstructured":"Lyne, P. D., Lamb, M. L. & Saeh, J. C. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular Docking and MM-GBSA scoring. J. Med. Chem. 49, 4805\u20134808. https:\/\/doi.org\/10.1021\/jm060522a (2006).","journal-title":"J. Med. Chem."},{"key":"94373_CR42","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu, C. Improving force field accuracy on challenging regimes of chemical space. J. Chem. Theory Comput. 17, 4291\u20134300. https:\/\/doi.org\/10.1021\/acs.jctc.1c00302 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"94373_CR43","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/prot.2310644","volume":"79","author":"J Li","year":"2011","unstructured":"Li, J. et al. The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. Proteins 79, 2794\u20132812. https:\/\/doi.org\/10.1002\/prot.2310644 (2011).","journal-title":"Proteins"},{"issue":"4","key":"94373_CR44","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1063\/1.463940","volume":"97","author":"GJ Martyna","year":"1992","unstructured":"Martyna, G. J., Klein, M. L. & Tuckerman, M. Nos\u00e9\u2013Hoover chains: the canonical ensemble via continuous dynamics. J. Chem. Phys. 97 (4), 2635\u20132643 (1992).","journal-title":"J. Chem. Phys."},{"issue":"1","key":"94373_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/14756366.2021.2007905","volume":"37","author":"MM Khalifa","year":"2021","unstructured":"Khalifa, M. M. et al. Topo II Inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J. Enzyme Inhib. Med. Chem. 37 (1), 299\u2013314. https:\/\/doi.org\/10.1080\/14756366.2021.2007905 (2021).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"11","key":"94373_CR46","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1021\/np50089a004","volume":"55","author":"NS Burres","year":"1992","unstructured":"Burres, N. S., Frigo, A., Rasmussen, R. R. & McAlpine, J. B. A colorimetric microassay for the detection of agents that interact with DNA. J. Nat. Prod. 55 (11), 1582\u20131587. https:\/\/doi.org\/10.1021\/np50089a004 (1992).","journal-title":"J. Nat. Prod."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94373-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94373-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94373-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:08:10Z","timestamp":1743116890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94373-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94373"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94373-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10607"}}